Avacopan is effective in inducing remission for MPA/GPA, regardless of changes in serum C5a levels: a single-center study in Japan

Avacopan is effective in inducing remission for MPA/GPA, regardless of changes in serum C5a levels: a single-center study in Japan

Abstract Background Avacopan, a selective oral C5a receptor antagonist, was approved for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) in 2021. However, there are still limited reports on its efficacy and safety in real-world settings, specifically regard...

Full description

Saved in:
Bibliographic Details
Main Authors: Yusuke Ushio, Hiromi Shimada, Risa Wakiya, Shusaku Nakashima, Taichi Miyagi, Koichi Sugihara, Rina Mino, Mao Mizusaki, Kanako Chujo, Naoto Manabe, Norimitsu Kadowaki, Hiroaki Dobashi
Format: Article
Language:English
Published: BMC 2025-08-01
Series:BMC Rheumatology
Subjects:
Avacopan
Microscopic polyangiitis
Granulomatosis with polyangiitis
Remission induction therapy
Serum C5a
Online Access:https://doi.org/10.1186/s41927-025-00555-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items